U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Advisory Letters
  5. Coochie Couture
  1. Advisory Letters

Coochie Couture

Black HHS-Blue FDA Logo



Food and Drug Administration
Silver Spring, MD 20993-0002


December 9, 2019                                                                    

Shana Hearvy
Coochie Couture
P.O. Box 251
Selden, NY 11784

RE: 3pc Herbal Detox Pearls and 6pc Herbal Detox Pearls

Dear Shana Hearvy:

This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your websites at https://coochiecouture.net/, https://www.instagram.com/coochiecouture_/, and https://www.facebook.com/coochiecouturee/ in November 2019 and has found that you take orders there for 3pc Herbal Detox Pearls and 6pc Herbal Detox Pearls. We also reviewed your social media websites at https://www.instagram.com/coochiecouture_/ and https://www.facebook.com/coochiecouturee/. Various claims and statements made on your websites establish that these products are drugs as defined in 21 U.S.C. § 321(g)(1)(B) because they are intended for the treatment, cure, mitigation, or prevention of disease. For example, your websites recommend or suggest the use of 3pc Herbal Detox Pearls and 6pc Herbal Detox Pearls to treat or prevent endometriosis and pelvic inflammatory disease. As explained further below, the introduction of these products into interstate commerce for such uses violates the Federal Food, Drug, and Cosmetic Act.

These products are also new drugs as defined under 21 U.S.C. § 321(p) because they are not generally recognized as safe and effective for the uses recommended or suggested in their labeling. Before a new drug may be marketed or otherwise introduced into interstate commerce, it must be approved by FDA on the basis of scientific data demonstrating that the drug is safe and effective under the conditions of use in its labeling. See 21 U.S.C. §§ 355(a) and 331(d). Your drug products do not have FDA-approved applications as required by 21 U.S.C. § 355.

We advise you to review all materials through which you communicate to consumers the intended uses of your products, and to either submit a new drug application (NDA) for products intended for use in treating, curing, mitigating, diagnosing, or preventing a disease or, alternatively, remove all statements indicating that your products are intended for such uses. This would include reviewing your websites, product labels, catalogs, brochures, flyers, package inserts, audio and video, ecommerce and social media accounts you operate (e.g., Amazon, eBay, Facebook and Twitter accounts), as well as any other promotional materials, and removing product claims, consumer testimonials, metatags, and anything else that states or implies that your products are useful in treating, curing, mitigating, diagnosing, or preventing diseases.

Within 30 calendar days of the date of this letter, please correct the violations described in this letter and notify FDA, via electronic mail at FDAadvisory@fda.hhs.gov, that the violations have been corrected. Include the Online Advisory Letter Reference number (located in the upper right portion of this letter) in all your communications to FDA regarding this matter.

After 30 days from the date of this letter, if your websites or other labeling continue to demonstrate that your products are intended to treat, cure, mitigate, or prevent diseases, the name of your firm and this letter will be posted on the FDA webpage for products illegally marketed for serious diseases.

This letter is not intended to be an all-inclusive review of your websites or a list of all violations of law that exist in connection with your products, your websites and other product labeling, or at your facilities. FDA expects you to take the necessary steps to ensure that all your products comply with the laws and regulations enforced by FDA.


The U.S. Food and Drug Administration


Back to Top